research use only
Cat.No.S9726
| Related Targets | Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras |
|---|---|
| Other FKBP Inhibitors | dTAG-13 Shield-1 (Shld1) AP20187 (B/B Homodimerizer) S107 hydrochloride dTAGV-1 TFA SAFit2 |
|
In vitro |
DMSO
: 100 mg/mL
(70.84 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 1411.63 | Formula | C78H98N4O20 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 195514-63-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | SMILES | CCC(C(=O)N1CCCCC1C(=O)OC(CCC2=CC(=C(OC)C=C2)OC)C3=CC(=CC=C3)OCC(=O)NCCNC(=O)COC4=CC=CC(=C4)C(CCC5=CC(=C(OC)C=C5)OC)OC(=O)C6CCCCN6C(=O)C(CC)C7=CC(=C(OC)C(=C7)OC)OC)C8=CC(=C(OC)C(=C8)OC)OC | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
FKBP fusion protein
|
|---|---|
| In vitro |
Rimiducid (AP1903) induces effective and dose-dependent apoptosis in the culture expressing dimer-dependent Fas constructors, indicating that it causes the activation of Fas signaling without interference from endogenous FKBP. |
| In vivo |
Eliciting a dose-dependent decrease in serum hGH levels with a half-maximal effective dose of 0.4±0.1 mg/kg, Rimiducid (AP1903) is functional in activating Fas signaling in vivo. |
References |
|
(data from https://clinicaltrials.gov, updated on 2026-05-15)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06066424 | RECRUITING | Solid Tumors |
M.D. Anderson Cancer Center |
2023-10-24 | PHASE1 |
| NCT07553390 | NOT_YET_RECRUITING | Breast Cancer |
M.D. Anderson Cancer Center |
2026-10-01 | PHASE1 |
| NCT06984341 | WITHDRAWN | Systemic Lupus Erythematosus |
Genentech, Inc. |
2026-06-30 | PHASE1 |
| NCT03741127 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Poseida Therapeutics, Inc. |
2018-10-29 | PHASE1 |
| NCT07164469 | NOT_YET_RECRUITING | Large B-cell Lymphoma; Hodgkin Lymphoma |
M.D. Anderson Cancer Center |
2026-12-28 | PHASE2 |
| NCT01494103 | ACTIVE_NOT_RECRUITING | Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Non Hodgkin Lymphoma; Hemophagocytic Lymphohistiocytosis; Familial Hemophagocytic Lymphohistiocytosis; Hemophagocytic Syndrome; Epstein Barr Virus Infection; X-linked Lymphoproliferative Disease |
Baylor College of Medicine |
2011-11 | PHASE1 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.